ClinicalTrials.gg
CompletedNCT06080555Updated Apr 18, 2024

Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia

A Phase 1 interventional study of Ferric Carboxymaltose Injection and Ferric Carboxymaltose Injection [Ferinject] in Iron Deficiency and Anaemia, sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd. Completed at 4 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing ferric carboxymaltose in Iron Deficiencies — 8 open to participants now, 8 under way, 2 of them phase 3. ferric carboxymaltose · Iron Deficiencies.

Enrollment
25th of 40
84 · median 134
Started
2023
with 1 other
Phase 1
2 of 40
none open now
Registered
32nd of 40
by date

Among the 40 studies testing ferric carboxymaltose in Iron Deficiencies, this one is the 25th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 1, and was the 32nd registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

8 of the 40 studies testing ferric carboxymaltose in Iron Deficiencies are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Iron Deficiencies studies recruiting now, 23 (42%) set no upper age limit and 28 (51%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing ferric carboxymaltose in Iron Deficiencies, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in participants with iron deficiency anaemia under fasting condition. The main questions it aims to answer are:

  • [Question 1] Is there significant difference in the pharmacokinetic profile between the ferric carboxymaltose injection (10 mL: 500 mg [calculated by iron]) provided by Sichuan Huiyu Pharmaceutical Co., Ltd. and the ferric carboxymaltose injection (trade name: Ferinject®, strength: 10 mL: 500 mg [calculated by iron]) held by Vifor France?
  • [Question 2] Is it safe for patient to take ferric carboxymaltose injection (10 mL: 500 mg [calculated by iron]) provided by Sichuan Huiyu Pharmaceutical Co., Ltd. under fasting condition? Participants will be randomly divided into two groups by stratified blocked randomization, with equal number of patients in each group,to receive test product or reference product according to the protocol below.
  • Dosing on D1: Group T (Test product) Group R (Reference product)
  • PK blood sample collection
  • Safety evaluation
03

Conditions studied

  • Iron Deficiency
  • Anaemia

Keywords

  • Bioequivalence
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:(all inclusion criteria must be met to be included)

  1. Participants with a thorough understanding of the content, process, and potential adverse reactions of the study, who have signed Form;
  2. Those able to complete the study as per the study protocol;
  3. Participants (including their partners) having no planning for pregnancy from the screening through 3 months after the last administration, and willing to take effective measures;
  4. Male and/or female participants aged 18-60 (including those aged 18 and 60);
  5. Male participants weighing not less than 50 kilograms and female participants weighing not less than 45 kilograms. (BMI) = weight (kg)/height 2 (m2), with a body mass index ranging from 18 to 30 kg/m2 (including both boundaries);
  6. Diagnosis of iron-deficiency anemia is confirmed during the screening process based on the following criteria (both criteria must be met): ① (Hb) \< 110 g/L (for females) or Hb \< 120 g/L (for males). ②Serum ferritin ≤ 100 ng/mL, or when the serum transferrin saturation (TSAT) is ≤ 30%, serum ferritin ≤ 300 ng/mL.

Exclusion Criteria: (meeting any one of these criteria will result in exclusion)

  1. Participants with an allergic constitution, such as asthma and eczema, or having known to iron, maltose or its analogues, metabolites;
  2. In addition to iron-deficiency anemia, participants will be excluded from the screening process if they have had any of the following conditions within the past 6 months: cardiovascular, digestive, respiratory, urinary, hematological, metabolic, immune, or neurological system diseases, or any active as determined by the investigator;
  3. Individuals with acute infection in previous 2 weeks prior to the screening visit;
  4. laboratory tests: (ALT) > 1.5 times the (× ULN); aspartate transaminase (AST) > 1.5 × ULN; total serum (TBiL) > 1.5 × ULN; albumin \< 30 g/L; count \< 90 × 109/L; neutrophil absolute count \< 1.3 × 109/L; \< 60 mL/min/1.73 m2 (estimated based on simplified Modification of Diet in Renal Disease (MDRD) formula);
  5. Serious arrhythmias showed in at screening period, such as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation accompanied by rapid ventricular response or supraventricular tachycardia, and are not suitable for the trial at the investigator's discretion;
  6. With history of iron storage diseases such as haemochromatosis; history of iron utilisation disorders such as sideroachrestic anaemia; history of haemoglobinopathy (such as Thalassemia); having symptomatic anemia requiring red blood cell infusion;
  7. Receiving IV iron therapy in previous 3 months prior to the screening visit, erythropoiesis stimulating agent (ESA) therapy and/or blood transfusion in previous 4 weeks prior to the screening visit, and oral iron or iron-containing products in previous 7 days prior to the screening visit;
  8. Receiving any prescription drugs that affect PK results in previous 14 days prior to the screening visit;
  9. Receiving any non-prescription drugs, traditional Chinese medicine, or healthcare products that affect PK results in previous 7 days prior to the screening visit;
  10. Individuals who consume an average of more than 5 cigarettes per day in previous 3 months prior to the screening visit;
  11. Individuals who have undergone surgeries within the past 3 months that might affect drug absorption, distribution, metabolism, or excretion, or those who are planning to undergo surgeries during the study period, will also be deemed ineligible to participate;
  12. Received drug or participated in other clinical trials within the preceding 3 months;
  13. Blood donation or significant blood loss in previous 3 months prior to the screening visit (> 400 mL, excluding menstrual blood loss in female participants);
  14. Female participants who are currently breastfeeding or have positive pregnancy test results during the screening period or clinical trials;
  15. People having viral hepatitis, such as or C, antibody positive, treponema pallidum antibody positive and rapid plasma reaction (RPR) positive; (patients with positive hepatitis B surface antigen alone can be subjected to additional test for HBV DNA, patients with positive antibody alone can be subjected to additional test for HCV RNA, and those with positive Treponema pallidum antibody alone can be subjected to additional test for RPR);
  16. Individuals with a history of drug abuse in previous 5 years prior to the screening visit or those who have used drugs in previous 3 months prior to the screening visit;
  17. Acute illness or concomitant medication from the screening stage to the study drug dosing;
  18. Having chocolate, or any food or drink containing caffeine or rich in xanthine 48 h before receiving the study drug;
  19. Regular drinkers in previous 3 months prior to the screening visit, i.e. those who consume an average of over 2 units of alcohol per day (1 unit = 360 mL of beer or 45 mL of 40% liquor or 150 mL of wine), or those who are unwilling to give up drinking or any alcoholic products during the trial period;
  20. Those with positive drug abuse screening or alcohol screening;
  21. Having special diet, such as grapefruit or products containing grapefruit ingredients, taking strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion, within 48 h before receiving the study drug;
  22. Those receiving non-inactivated vaccine in previous 14 days prior to the screening visit or planning to receive vaccine during the study period;
  23. Those who cannot tolerate venipuncture or have a history of fear of needles or hemophobia;
  24. Other circumstances that may increase the risk of the participant or interfere with the evaluation or results of the study at the investigator's discretion;
  25. Participants not suitable for the trial at the investigator's discretion.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Test product-Ferric carboxymaltose Injection provided by SichuanHuiyuPharma

    Drug: Ferric Carboxymaltose Injection

  • Active comparator
    Reference product-marketed by Vifor France

    Drug: Ferric Carboxymaltose Injection [Ferinject]

Interventions

  • For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.

  • For the R group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the reference product (trade name: Ferinject®) (R, 10 mL: 500 mg elemental iron) via intravenous injection on an empty stomach, at a continuous rate for 5 min, with a speed of 2 mL/min.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter of total iron in serum: Cmax

    Cmax is the peak concentration of total iron in serum. It is directly obtained from observed blood drug concentration-time data.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

  2. Pharmacokinetic parameter of total iron in serum: AUC0-t

    AUC0-t is the area under the concentration curve from dosing to the last measurable blood drug concentration.It is calculated using the linear trapezoidal rule.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

  3. Pharmacokinetic parameter of transferrin bound iron in serum: Cmax

    Cmax is the peak concentration of transferrin bound iron in serum. It is directly obtained from observed blood drug concentration-time data.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

  4. Pharmacokinetic parameter of transferrin bound iron in serum: AUC0-t

    AUC0-t is the area under the concentration curve from dosing to the last measurable blood drug concentration.It is calculated using the linear trapezoidal rule.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

Secondary outcomes

  1. Pharmacokinetic parameter of total iron in serum: AUC0-∞

    AUC0-∞ is the area under the curve from dosing to extrapolated infinite time. AUC0-∞ = AUC0-t + Ct / λz, where Ct is the last measurable concentration, and λz is the elimination rate constant.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

  2. Pharmacokinetic parameter of total iron in serum: Tmax

    Tmax is the time to reach maximum concentration of total serum iron.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

  3. Pharmacokinetic parameter of total iron in serum: t1/2

    t1/2 is the terminal elimination half-life of total serum iron. It is calculated as ln2 / λz.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

  4. Pharmacokinetic parameter of total iron in serum:λz

    λz is the elimination rate constant of total serum iron. It is calculated as the negative reciprocal of the slope of the terminal phase of the logarithm-linear drug concentration-time curve using linear regression.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

  5. Pharmacokinetic parameter of transferrin bound iron in serum: AUC0-∞

    AUC0-∞ is the area under the curve from dosing to extrapolated infinite time. AUC0-∞ = AUC0-t + Ct / λz, where Ct is the last measurable concentration, and λz is the elimination rate constant.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

  6. Pharmacokinetic parameter of transferrin bound iron in serum: Tmax

    Tmax is the time to reach maximum concentration of serum transferrin bound iron.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

  7. Pharmacokinetic parameter of transferrin bound iron in serum: t1/2

    t1/2 is the terminal elimination half-life of transferrin bound iron. It is calculated as ln2 / λz.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

  8. Pharmacokinetic parameter of transferrin bound iron in serum:λz

    λz is the elimination rate constant of transferrin bound iron. It is calculated as the negative reciprocal of the slope of the terminal phase of the logarithm-linear drug concentration-time curve using linear regression.

    Time frame: 24hours,12hours,0hour before administration, and 5minutes,10minutes,15minutes,30minutes,45minutes,1hour,1.5hours,2hours,4hours,6hours,8hours,10hours,12hours,24hours,36hours,48hours,72hours,96hours,120hours and 144hours after administration.

07

Study locations

4 sites
  • Boji medical technology (Beijing) co., Ltd
    Beijing, Beijing, China
  • Boji Medical Technology Co., Ltd
    Guangzhou, Guangdong, China
  • Suzhou Guochen Biotek Co., Ltd
    Suzhou, Jiangsu, China
  • Phase I Clinical Trial Department, The First Hospital of Jilin University
    Changchun, Jilin, China
08

References and documents

Publications

  • Ikuta K, Shimura A, Terauchi M, Yoshii K, Kawabata Y. Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia. Int J Hematol. 2018 May;107(5):519-527. doi: 10.1007/s12185-018-2400-z. Epub 2018 Jan 22. PubMed 29357079 ↗
  • Ding Y, Zhu X, Li X, Zhang H, Wu M, Liu J, Palmen M, Roubert B, Li C. Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-deficiency Anemia. Clin Ther. 2020 Feb;42(2):276-285. doi: 10.1016/j.clinthera.2019.12.010. Epub 2020 Jan 11. PubMed 31937462 ↗
  • Ferric Carboxymaltose Injection Package Insert. Vifor (International) Inc
  • Multidisciplinary Expert Consensus on Diagnosis, Treatment, and Prevention of Iron Deficiency and Iron-Deficiency Anemia by the Hematology Branch of the Chinese Medical Association (Anemia Group) [J]. Chinese Medical Journal, 2022, 102(41):3246-3256

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jan 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 12, 2023
StartActual
Oct 9, 2023
Primary completionActual
Jan 22, 2024
CompletionActual
Mar 22, 2024
Last update
Apr 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06080555
Collaborators
The First Hospital of Jilin University, Suzhou Guochen Biotek Co., Ltd., Boji Data Technology (Beijing) Co., Ltd., Boji Medical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Oct 12, 2023
Start date
Oct 9, 2023
Primary completion
Jan 22, 2024
Completion
Mar 22, 2024
Last update
Apr 18, 2024

Study contacts

Li Xiang
study director · Sichuan Huiyu Pharmaceutical Co., Ltd

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion